Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome

Juszczyński, Przemysław; Kalinka, Ewa; Bienvenu, Jacques; Woszczek, Grzegorz; Borowiec, Maciej; Robak, Tadeusz; Kowalski, M.; Lech-Maranda, Ewa; Baseggio, Lucile; Coiffier, Bertrand; Salles, Gilles; Warzocha, Krzysztof

doi:10.1182/blood-2002-02-0654

Cited by 77 publications

(58 citation statements)

References 23 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[40][41][42][43][44][45][46] With the introduction of novel therapies, these efforts will ultimately allow clinicians to increasingly focus on more individualized approaches, with the aim to tailor treatment. Family history of lymphoma is a well-known risk factor for developing lymphoma.…”

Section: Survival In Familial Lymphomamentioning

confidence: 99%

“…[40][41][42][43][44][45][46][47] To our knowledge, only a few small studies have assessed outcome in patients with familial lymphoma. In an observational study comparing the prognosis of patients with lymphoma, leukemia, or myeloma from 55 multiple-case and 109 single-case families, patients from multiple-case families had an 8.3% poorer survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma

Anderson

Pfeiffer

Rapkin

et al. 2008

JCO

View full text Add to dashboard Cite

A B S T R A C T PurposeGenetic factors are important in the etiology and pathogenesis of chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). Only a few small studies have assessed clinical characteristics and prognosis for familial patients, with inconsistent findings. MethodsUsing population-based registries from Sweden and Denmark, 7,749 patients with CLL, 7,476 patients with HL, and 25,801 patients with NHL with linkable first-degree relatives were identified. Kaplan-Meier curves were constructed to compare survival in patients with lymphoma with and without a family history of lymphoma. The risk of dying was assessed using adjusted Cox proportional hazard models. ResultsWe found 85 patients with CLL (1.10%), 95 patients with HL (1.28%), and 206 patients with NHL (0.80%) with a family history of any lymphoma. Five-year mortality was similar for patients with CLL (hazard ratio [HR], 1.28; 95% CI, 0.95 to 1.72), HL (HR, 0.78; 95% CI, 0.49 to 1.25), and NHL (HR, 0.91; 95% CI, 0.74 to 1.12) versus without a family history of any lymphoma. Mortality was also similar for patients with versus without a family history of the same lymphoma. T-cell/ anaplastic lymphoma patients with a family history of NHL had poorer outcome 5-years after diagnosis (HR, 5.38; 95% CI, 1.65 to 17.52). Results were similar for 10 years of follow-up. ConclusionWith the exception of T-cell/anaplastic lymphoma, survival patterns for patients with CLL, HL, and NHL with a family history of lymphoma were similar to those for sporadic patients, suggesting that most familial lymphomas do not have an altered clinical course. Our findings provide no evidence to modify therapeutic strategies for patients with CLL, HL, or NHL based solely on family history. J Clin

show abstract

Section: Survival In Familial Lymphomamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma

Anderson

Pfeiffer

Rapkin

et al. 2008

JCO

View full text Add to dashboard Cite

show abstract

“…Thus far, no high-penetrance gene mutation has been identified for non-Hodgkin lymphoma but a 2-fold increased risk in individuals with first-degree relatives who had non-Hodgkin lymphoma or other hematopoietic disease (3)(4)(5) provides strong evidence for genetic susceptibility to non-Hodgkin lymphoma. To date, investigations of immune gene variations in lymphomas have included a limited number of genes, polymorphisms, and non-Hodgkin lymphoma outcomes (6)(7)(8)(9)(10)(11). Recent gene expression studies further implicate host inflammatory responses (12) and the nuclear factor-nB (NF-nB) pathway, thus supporting the conceivable role for polymorphic alleles of key immunoregulatory genes and the risk for non-Hodgkin lymphoma (13).…”

Section: Introductionmentioning

confidence: 99%

Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma

et al. 2006

View full text Add to dashboard Cite

Profound disruption of immune function is an established risk factor for non-Hodgkin lymphoma. We report here a large-scale evaluation of common genetic variants in immune genes and their role in lymphoma. We genotyped 57 single nucleotide polymorphisms (SNP) from 36 candidate immune genes in 1,172 non-Hodgkin lymphoma cases and 982 population-based controls from a US multicenter study. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) for the association between individual SNP and haplotypes with non-Hodgkin lymphoma overall and five well-defined subtypes. A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-A and lymphotoxin-A (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007). A functional nonsynonymous SNP in the innate immune gene Fcg receptor 2A (FCGR2A; rs1801274) was also associated with non-Hodgkin lymphoma; AG and AA genotypes were associated with a 1.26-fold (95% CI, 1.01-1.56) and 1.41-fold (95% CI, 1.10-1.81) increased risk, respectively (P trend = 0.006). Among non-Hodgkin lymphoma subtypes, the association with FCGR2A was pronounced for follicular and small lymphocytic lymphomas. In conclusion, common variants in genes influencing proinflammatory and innate immune responses were associated with non-Hodgkin lymphoma risk overall and their effects could vary by subtype. Our results require replication but potentially provide important clues for investigating common genetic variants as susceptibility factors and in disease outcomes, treatment responses, and immunotherapy targets.

show abstract

“…[17][18][19][20][21][22] In addition, some of these variants have also been associated with progression-free or overall NHL survival in prognostic cohort studies. 20,21,23,24 However, studies of prognosis after diagnosis have been limited to an evaluation of a small number of genes (Յ 3) in small numbers of patients with follicular lymphoma (Ͻ 125).…”

Section: Introductionmentioning

confidence: 99%